After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
We received an updated WNV package insert; please note the manufacturer and license number has been ...